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Abstract
Background—In the era of effective antiretroviral treatment (ART) CD4:CD8 ratio is proposed 
as a potential marker for HIV-positive (HIV+) patients at increased risk for non-AIDS 
comorbidities. The current study aims to compare CD4:CD8 ratio between Asian and Caucasian 
HIV+ patients.
Methods—HIV+ patients from the Australian HIV Observational Database (AHOD) and the 
TREAT Asia HIV Observational Database (TAHOD) meeting specific criteria were included. In 
these analyses Asian and Caucasian status were defined by cohort. Factors associated with a low 
CD4:CD8 ratio (cut-off <0.2) prior to ART commencement, and with achieving a normal 
CD4:CD8 ratio (>1) at 12 and 24 months post ART commencement were assessed using logistic 
regression.
Results—There were 591 patients from AHOD and 2620 patients from TAHOD who met the 
inclusion criteria. TAHOD patients had a significantly (p<0.001) lower odds of having a baseline 
(prior to ART initiation) CD4:CD8 ratio greater than 0.2. After 12 months of ART, AHOD patients 
were more than twice as likely to achieve a normal CD4:CD8 ratio compared to TAHOD patients 
(15% vs 6%). However, after adjustment for confounding factors there was no significant 
difference between cohorts in the odds of achieving a CD4:CD8 ratio > 1 (p=0.475).
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Discussion—We found a significantly lower CD4:CD8 ratio prior to commencing ART in 
TAHOD compared to AHOD even after adjusting for confounders. However, after adjustment, 
there was no significant difference between the cohorts in odds of achieving normal ratio. Baseline 
CD4+ and CD8+ counts seem to be the main driver for this difference between these two 
populations.
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Introduction
HIV positive (HIV+) patients have significantly improved survival in the current era of 
effective antiretroviral therapy (ART). Yet mortality rates still remain elevated compared to 
HIV-negative people and HIV+ patients are increasingly experiencing many age related 
comorbidities. In addition to the natural ageing process, and lifestyle factors, HIV infection 
itself is commonly implicated due to the ongoing immune activation and inflammation [1].
CD4 lymphocyte (CD4+) count has been the single most important surrogate marker of 
mortality risk in HIV+ patients. The availability of effective ART means the majority of 
patients now achieve and maintain high CD4+ counts. For patients with CD4+ counts >500 
cells/mm3 other surrogate markers of immune function, such as CD4:CD8 ratio, are being 
investigated for their capacity to differentiate patients who are at increased risk of non-
infectious comorbidities.
In HIV-negative people an inverted CD4:CD8 ratio is an indicator of immune-senescence 
and an independent predictor of all-cause mortality [2, 3]. Prior to the availability of ART, 
HIV infection lead to a dramatic decrease in CD4+count along with increasing CD8+ counts 
resulting in an inverted CD4:CD8 ratio (<1). In the current ART era, although most patients 
begin ART with an inverted CD4:CD8 ratio, studies report that overtime ratios reach normal 
levels (ratio >1) for some patients. However, these studies also report that the rate of 
normalisation is quite slow and in some cases as many as 70% of patients have been reported 
to not having achieved a normal ratio after 5 years of ART[4, 5], suggesting ongoing 
immune dysregulation. Studies have also shown that an inverted CD4:CD8 ratio is 
independently associated with predicting morbidity and mortality over many years among 
HIV positive patients [5-7]. These studies also suggest a loss in the predictive value of CD4+ 
count.
It is known that Asian and Caucasian populations have different absolute CD4+ counts. 
Previous work comparing an Asian HIV+ cohort (TAHOD) with predominately Caucasian 
HIV+ cohorts (Aquitaine and AHOD) showed that for any given CD4 percentage [CD4% 
strata as indicator of disease stage] Asians had a lower CD4+ count pre-treatment [8], and 
have slightly lower CD4+ count responses after starting ART, even after adjusting for 
baseline CD4+ counts[9] compared to Caucasians. Further follow-up work from these 
investigators reported that these differences were not clinically significant [10]. It is not 
known whether this variability in CD4+ count between Caucasian and Asian populations is 
also evident when investigating the CD4:CD8 ratio. The aim of this study is to compare the 
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CD4:CD8 ratio between Asian and Caucasian HIV+ patients, prior to initiation of 
antiretroviral therapy, and at 12 and 24 months post commencement of ART.
Methods
Study population
The Australian HIV Observational Database (AHOD) and the TREAT Asia HIV 
Observational Database (TAHOD) are observational cohort studies of HIV positive patients 
in Australia and Asia. AHOD and TAHOD have similar methodologies which have 
previously been explained in detail [11, 12]. Briefly AHOD and TAHOD commenced in 
1999 and 2003 and include 30 clinical sites throughout Australia (AHOD) and 20 clinical 
sites throughout 12 countries in the Asia Pacific region (TAHOD). In 2014 AHOD was 
expanded to include two sites in New Zealand. Retrospective and prospective HIV related 
data are recorded for patients recruited to these cohorts. These data include basic 
demographics, antiretroviral treatment uptake as well as immunological (CD4+ and CD8+ 
count) and virological markers of HIV disease, AIDS diagnoses and coinfections with 
Hepatitis B (HBV) and Hepatitis C (HCV). Date and cause of death are also reported. These 
cohorts are also currently part of the International Epidemiology Databases to Evaluate 
AIDS initiative (IeDEA) global cohort consortium [13]. Ethics approval for both AHOD and 
TAHOD are obtained from the UNSW Australia Human Research Ethics Committee and 
from institutional review boards at all sites and the coordinating centre at TREAT Asia. All 
AHOD and TAHOD study procedures are in accordance with the 1975 Helsinki declaration.
Inclusion criteria
For this analysis, patients in AHOD and TAHOD were included if they met the following 
criteria: previously treatment naïve patients who commenced combination antiretroviral 
therapy (ART) on or after 1 January 2000 and remained on treatment for at least 14 days. All 
included patients had at least one CD4:CD8 ratio measurement within 12 months prior to 
commencing ART, and at least one CD4:CD8 ratio measurement at least 3 months (to ensure 
sufficient time for impact of ART) after commencing ART. Ethnicity is inconsistently 
available in AHOD, with approximately half of the cohort with known ethnicity, of whom 
more than 90% report Caucasian. TAHOD has ethnicity consistently reported with 
approximately 95% known to be Asian, and less than 1% reported as White/Caucasian. 
Consistent with previous comparisons of AHOD and TAHOD populations [10], in these 
analyses, it is assumed that AHOD largely represents a Caucasian population, whilst 
TAHOD an Asian population. All Asian/Caucasian comparisons were therefore be defined 
by cohort.
Statistical analyses—For all analyses, baseline is defined as ART commencement date, 
and the closest measurement prior to the ART start date from herein will be referred to as the 
baseline measure. The primary outcomes of interest are pre-ART CD4:CD8 ratio and normal 
CD4:CD8 ratio at 12 months after ART initiation in both AHOD and TAHOD. Baseline 
characteristics were summarised by cohort. Median and interquartile range (IQR) for 
CD4:CD8 ratio were calculated by averaging individual patient measures at each time point, 
then averaging over the respective cohorts at each time point, and then illustrated graphically 
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by month over 5 years stratified by cohort. These were estimated on available data only and 
there was no imputation of missing data or observation carried forward. Data were censored 
at 5 years, last follow-up visit or death (whichever came first). In both cohorts lost to follow-
up (ltf) and death rates are low (AHOD: ltf 3.9/100 person years (py); mortality rate: 
1.04/100 py. TAHOD: ltf 2.7/100 py; mortality rate: 0.9/100 py). The proportion of patients 
with an inverted CD4:CD8 ratio at baseline who achieve a normalised ratio (> 1) after 
commencing ART for both AHOD and TAHOD were also calculated.
Factors associated with an inverted CD4:CD8 ratio before commencing ART and for 
achieving a normal ratio (>1) at 12 and 24 months post treatment commencement were 
assessed using univariate and multivariate logistic regression methods. Only patients with 
follow-up measures within a 12 and 24 month time window (3 months on either side) were 
included, and taking the value closest to 12 and 24 months were used. For both outcomes 
factors assessed in addition to cohort included age (at time of ART start), sex, HBV and 
HCV coinfection status (ever), mode of HIV exposure (men who have sex with men (MSM), 
heterosexual contract, injecting drug use, and other/missing), AIDS diagnoses (prior to ART 
start) and ART class. ART class, defined as three or more antiretrovirals with regimens 
categorised as follows: a) non-nucleoside reverse transcriptase inhibitor (NNRTI) and 
excluding both protease inhibitors (PI) and integrase inhibitors (InSTI), b) PI excluding 
NNRTI and InSTI, c) InSTI, and d) Other. In addition, for the outcome normalisation of 
CD4:CD8 ratio analysis, baseline CD4+ and CD8+ count (cells/mm3), and CD4:CD8 ratio 
as a continuous variable, were also included. HIV viral load was not included as a factor for 
assessment for any of the regressions as it is differentially reported in TAHOD compared 
with AHOD (>30% missing viral load at baseline). For all regression analyses, factors with 
p<0.05 in univariate analysis were assessed in multivariate analysis. Multivariate models 
were built using backward stepwise regression methods and p value of <0.05 was used to 
determine factors independently associated with CD4:CD8 ratio. Guidelines for 
commencing ART at specific CD4+ count thresholds have changed over time and vary 
across countries. In these analyses, in addition to measuring and adjusting for CD4+ count, 
we also adjusted all regression analyses by calendar year to further account for changes in 
these guidelines.
Sensitivity analyses—We undertook additional sensitivity analyses where we limited the 
analysis population to 1. patients who commenced ART with CD4 counts above 250 
cells/mm3 and 2. Patients whose baseline CD4 measure was within 6 months prior to ART 
start (as opposed to 12 months). We re-assessed factors associated with achieving a normal 
ratio 12 months and 24 months after commencing ART in these populations.
Results
A total of 4125 patients from AHOD and 8710 patients from TAHOD were recruited by 
March 2015 and September 2015, respectively. Of these, 591 patients from AHOD and 2620 
patients from TAHOD met the inclusion criteria. The main reason for exclusion in AHOD 
(76%) was due to initiating ART prior to 1 January 2000 and/or previous treatment. In 
TAHOD the main reason for exclusion (54%) was due to the absence of the required 
CD4:CD8 measure before commencing ART or after 3 months of follow-up.
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Patient characteristics of the included populations stratified by cohort are presented in Table 
1 and Table 2. The cohorts differed in particular in terms of sex, 93% of the AHOD cohort 
were men compared to 80% in TAHOD. Median age at time of commencing ART (baseline) 
was 41 (IQR 34-48) years for AHOD patients and 36 years (IQR: 30-42) in TAHOD. Mode 
of HIV exposure was predominately male to male sex in AHOD (71%), whilst in TAHOD 
the main mode of exposure was heterosexual contact (52%) followed by male to male sex 
(36%). Median baseline CD4+ count (cells/mm3) was 290 (IQR: 197-446) for AHOD and 
152 (IQR: 54-255) for TAHOD. Seven percent of AHOD patients had an AIDS-defining 
illness diagnosed prior to baseline compared to 40% of TAHOD patients. Starting ART 
combination varied between cohorts, the large majority of TAHOD patients (73%) 
commenced with an NNRTI compared with just over half (54%) of AHOD patients. A 
further 31% of AHOD patients commenced ART with a combination including a protease 
inhibitor (PI) or other antiretroviral (9%).
The most recent CD4:CD8 ratio prior to commencing ART was low in both cohorts with a 
median of 0.30 (IQR: 0.19-0.48) in AHOD and a median of 0.18 (IQR: 0.09-0.30) in 
TAHOD respectively. The TAHOD cohort was almost 50% less likely to have a CD4:CD8 
ratio above the overall cohort median of 0.2 (odds ratio (OR): 0.493, p<0.001) and having a 
prior AIDS diagnosis was also significantly associated with lower odds of having a baseline 
CD4:CD8 ratio above 0.2 (OR 0.361, p<0.001). Patients who report mode of HIV exposure 
as MSM were approximately 40% more likely to have a baseline ratio above 0.2 compared 
with either heterosexual contact group or IDU (p<0.001) (Table 3).
Of the 538 AHOD and 2092 TAHOD patients that had an available CD4:CD8 ratio measure 
at 12 months following ART commencement, 17% of AHOD and 7% of TAHOD patients 
achieved a normal (>1.0) ratio. Factors independently associated with achieving a normal 
ratio at month 12 are shown in Table 4. In univariate analyses AHOD cohort (p<0.001), 
increasing age per 10 years (p=0.047), MSM as mode of HIV exposure (p=0.005), increased 
CD4 cell count (p<0.001) and decreased CD8 count (p=0.001), increasing baseline 
CD4:CD8 ratio (p<0.001) and commencing ART with a protease inhibitor (PI) (p=0.02) or 
an HIV integrase inhibitor (INSTI) (p<0.001) compared with an NNRTI had an increased 
odds of achieving a normal ratio by 12 months. In multivariate analyses, factors that 
remained independently significantly associated with achieving a normal ratio were 
increasing age per 10 years (p=0.041), increasing baseline CD4+ count (per 20 cells/mm3) 
(p=0.002), decreasing CD8 count (p=0.038), increasing baseline ratio (p<0.001) and not 
having a prior AIDS diagnosis (p=0.024). Only patients who commenced with an InSTI had 
increased odds of a normal ratio at 12 months compared to patients who commenced with an 
NNRTI (p=0.002). After adjustment for these confounders, cohort was no longer significant 
(p=0.475). At 24 months post ART, of the 460 and 1657 AHOD and TAHOD patients with 
an available CD4:CD8 measure, 21% and 10% respectively had achieved a normal ratio. By 
this time point, however, CD8+ count, age and ART class were no longer confounding 
factors for normalisation (data not shown).
Over the entire follow-up period, 30% and 14% of all AHOD and TAHOD patients achieved 
a normal CD4:CD8 ratio. In Figure 1 the change in CD4:CD8 ratio over 60 months from 
commencing ART is presented for both AHOD and TAHOD. Despite commencing ART 
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with varying baseline CD4:CD8 ratios, both cohorts show an increasing CD4:CD8 ratio over 
time. Figure 2a and 2b also show that the change in ratio is driven by increasing CD4+ 
counts and decreasing CD8+ counts. However, as also shown in Figure 1, the median ratio 
for both cohorts does not approach or exceed 1.
Sensitivity analyses
When including only patients with a baseline above 250 cells/mm3 we found that baseline 
CD4 and CD8 counts were no longer significant, although female gender was now twice as 
likely to achieve a normal CD4:CD8 ratio. However, as with the analyses reported above, 
cohort was not statistically significant in multivariate analyses even after adjustment for the 
final significant model (OR: 1.134, confidence interval 0.750 – 1.712). Among patients with 
a baseline CD4 measure within 6 months prior to ART start, we found no difference in the 
final multivariate model to that reported above, and after adjustment cohort again was not an 
independently significant factor.
Conclusion
In this study we examined whether there were significant differences in CD4:CD8 ratio prior 
to commencing ART and in response to ART between Asian and Caucasian populations. We 
found a significantly lower CD4:CD8 ratio among Asian populations in TAHOD prior to 
commencing ART even after adjusting for absolute CD4+ and CD8+ counts and other 
confounders. Although CD4:CD8 ratio progressively increased for both AHOD and TAHOD 
for up to 5 years after commencing ART, only 30% of AHOD and fewer still of TAHOD 
(14%) achieved a normal ratio during follow-up. Despite fewer TAHOD patients reaching a 
normal ratio, after adjustment there was no significant difference between the cohorts in 
odds of achieving a normal ratio. Baseline CD4+ and CD8+ counts seem to be the main 
driver for this difference between these two populations.
TAHOD patients had lower CD4+ and CD8+ counts prior to commencing ART, and 
consequently a lower CD4:CD8 ratio at baseline. The significantly lower ratio compared to 
AHOD may be explained due to varying guidelines for commencing treatment within and 
across the region, often with recommended treatment commencement at lower CD4+ counts 
in Asia compared with Australia, as well as likely later presentation in the Asia region. 
However, even after adjustment for other significant factors, baseline CD4:CD8 ratio was 
significantly lower for TAHOD. In our study, prior AIDS diagnoses (indicator of later 
presentation), heterosexual mode of HIV exposure, and commencing ART with an NNRTI 
were also independently associated with having a lower CD4:CD8 ratio at baseline, and 
largely reflect the TAHOD cohort.
Once ART is commenced, both cohorts demonstrated an increasing CD4:CD8 ratio over 5 
years. In absolute terms CD4:CD8 ratio remained lower in TAHOD and significantly fewer 
patients achieved a normal ratio by 12 and 24 months after commencing ART. We have 
previously shown when comparing TAHOD to the predominately Caucasian Aquitaine 
cohort that Asians tended to have lower total lymphocyte counts and correspondingly lower 
CD4+ count [8]; however, follow-up work showed that these differences were not clinically 
significant [10]. In the current analysis, once adjusted for key factors there was no 
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significant difference between the cohorts. Immune status at baseline was the key 
contributing factor for normalisation. Patients with higher baseline CD4+ count, lower 
baseline CD8+ count, higher CD4:CD8 ratio at baseline, and not having a prior AIDS 
diagnosis were all significantly associated with normalisation at 12 months. Similar 
associated factors were also identified at month 24 except baseline CD8+ count was no 
longer significant. It has been suggested in the literature, in the presence of universal 
treatment and generally high CD4+ counts, that CD4:CD8 ratio might be more useful for 
predicting disease progression [6, 14]. However, our findings highlight the importance 
CD4+ count in explaining how CD4:CD8 ratio changes over time. Other studies have also 
suggested that older age, MSM and IDU as mode of HIV exposure, as well as starting ART 
regimen (AZT, 3TC or d4T compared with tenofovir and emtricitabine) also contribute to 
lower odds of achieving a normal ratio [5]. In our study older age and commencing ART 
with a PI or InSTI as opposed to an NNRTI were associated with increased likelihood of 
normalising by 12 months. It is likely that the treatment effects demonstrated in our study 
are due to the difference in treatment available as starting regimen in Asia compared to 
Australia. In Australia and among higher income countries of Asia, PI regimens and more 
recently InSTI regimens were used as first line therapy. PIs have been shown to boost CD4+ 
counts more than NNRTIs [15]. However, by 24 months starting ART regimen was not 
significant. Although other studies have found older age to be associated with not achieving 
a normal ratio [5, 16], we found the reverse. In our study older age was associated with 
increased odds of achieving a normal ratio at least in the first year. This might be due to an 
older AHOD cohort compared to TAHOD and also due to better treatment adherence, or 
monitoring of patients in AHOD.
Lower starting CD4:CD8 ratio is the likely reason CD4:CD8 ratio remained lower for the 
TAHOD cohort even after 5 years of ART. Studies have shown that early treatment initiation 
(early infection) compared to delayed treatment (chronic infection) allows for greater 
recovery of the CD4:CD8 ratio [17, 18], and that a low CD4:CD8 ratio prior to initiation of 
ART was associated with a decreased probability of achieving CD4+ counts above 500 
cells/mm3 [6, 19]. Leung et al for instance reported normalisation in 6% of patients who 
commenced ART at a CD4+ count below 200 cells/mm3 compared to 21% of patients who 
commenced above 350 cells/mm3 [4]. Approximately 30% and 14% of AHOD and TAHOD 
participants achieved a normal ratio after 5 years. The proportion of patients with normal 
ratios reported in the ICONA cohort [5] (4% at 1 year, 12% by 2 years and 29% by 5 years) 
were similar to the AHOD cohort (most likely reflecting similar treatment availability and 
starting guidelines), while slightly lower rates (7%) over a median of 4 years were reported 
by Leung et [4]. Ongoing immune activation is suggested as underlying the low rates of 
normalisation among HIV+ patients [20]. Although CD4+ count in our study is shown to 
recover considerably over 5 years, CD8+ count only marginally declined over the same 
period which might explain the low rate of normalisation in our study. Failure of CD8+ 
count to adequately decrease after ART is initiated, suggests ongoing immune activation and 
inflammation, as an important factor for the failure of the CD4:CD8 to normalise. Helleberg 
et al 2015 examined the trajectories of CD8+ count before and after ART in 3882 HIV+ 
patients [21], and showed that CD8+ count was elevated during untreated HIV infection and 
remained elevated through 10 years of ART.
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Lymphocyte activation, immune senescence and coinfections have also been attributed to 
failure to achieve a normal CD4:CD8 ratio. In our study ever being co-infected with HBV 
was associated with significantly decreased odds of achieving a normal ratio by 24 months, 
but there was no other significant association for either HBV or HCV coinfections for any of 
the other outcomes that we assessed. Saracino et al 2014 [16] reported no significant 
association with HBV, HCV or CMV infections. Whilst in the ICONA cohort, a negative 
CMV serology result was associated with the ratio normalising [5]. Similar associations with 
CMV positivity were also reported by Caby et al 2016 [22]. CMV serology was not 
available for assessment in our study.
A major strength of our study is that the cohorts were established using similar 
methodologies, with a significant number of years of data collection and follow-up. 
However, there are some limitations. First, the two cohorts are very heterogeneous, with 
varying treatment patterns and monitoring. AHOD is generally an older cohort in which the 
majority of patients commenced treatment pre-1996. In order to make the cohorts more 
comparable we limited the AHOD population to commencing treatment after 2000. 
However, this reduced the sample population of AHOD considerably. Viral load monitoring 
also differed considerably between the cohorts, with less frequent testing in TAHOD, as 
such we could not assess viral load as a covariate. We used cohort as a surrogate for whether 
patients were Caucasian or Asian as ethnicity data is incomplete in AHOD for several 
contributing sites. It is possible that some AHOD patients are of Asian ethnicity therefore 
resulting in misclassification; however, where ethnicity is recorded in AHOD (∼ 50%), more 
than 90% are Caucasians. Both cohorts are also select populations and whether these 
findings are generalizable to the wider population is not known. Finally, due to the 
observational nature of our study, we cannot exclude the risk of unmeasured confounding. It 
is also possible that in our analyses, patients lost to follow-up, or without available data at 12 
and 24 months after ART initiation, might cause some selection bias. When we compared 
patients with and without data at these time points, there was some variability for some of 
the subcategories, though these differences mostly can be explained by smaller sample size 
of the populations without data at these time points.
The overall objective of our study was to determine whether CD4:CD8 ratio in Asian 
populations are similar to Caucasian populations. In previous work by our group, lower 
CD4+ counts in TAHOD compared to AHOD did not translate to an increase in mortality 
risk [10]. Several studies have investigated CD4:CD8 ratio as a useful independent predictor 
for disease progression, and have shown that a lower CD4:CD8 ratio in ART treated 
populations increases the risk of non-AIDS mortality and morbidity [7, 14, 17]. However, 
our data suggest that the main reason for the lower CD4:CD8 ratio in the Asian cohort is 
lower CD4+ count when ART is commenced. As treatment availability and access improves 
across the region and patients commence treatment earlier, the lower starting CD4:CD8 ratio 
in Asia is likely to disappear. Nevertheless, future work will compare these cohorts to 
investigate the impact of CD4:CD8 ratio on mortality and serious non-AIDS clinical 
endpoints.
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Figure 1. Median CD4:CD8 ratio over 5 years by cohort
*Numbers at month 0, 18, 36 and 60: AHOD - 591, 510, 361 and 204; TAHOD – 2620, 
2238, 1371, 752.
IQR: Interquartile range
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Figure 2. Median CD4 cells/mm3 and CD8 cells/mm3 over 5 years by cohort
IQR: Interquartile range
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